1. Cancer statistics, 2021;Siegel;CA Cancer J Clin,2021
2. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship;Molina;Mayo Clin Proc,2008
3. Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer;Poels;Nat Commun,2021
4. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER);Shi;J Thorac Oncol,2014
5. A multifunctional nanotheranostic agent potentiates erlotinib to EGFR wild-type non-small cell lung cancer;Wang;Bioact Mater,2022